Parallel Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Parallel Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.17K	Hold	25	–	–	﹤0.01%	3343
2025 Q4	$2.68K	Hold	25	–	–	﹤0.01%	3056
2025 Q3	$2.52K	Buy	25 +6	+32%	+$557	﹤0.01%	2992
2025 Q2	$1.2K	Hold	19	–	–	﹤0.01%	3164
2025 Q1	$1.01K	Hold	19	–	–	﹤0.01%	3127
2024 Q4	$1.06K	Hold	19	–	–	﹤0.01%	3101
2024 Q3	$995	Buy	19 +14	+280%	+$671	﹤0.01%	3037
2024 Q2	$205	Hold	5	–	–	﹤0.01%	3200
2024 Q1	$217	Hold	5	–	–	﹤0.01%	3140
2023 Q4	$230	Buy	+5	New	+$158	﹤0.01%	3153
2022 Q1	–	Sell	-50	Closed	–	–	3239
2021 Q4	$0	Sell	50 -131	-72%	-$1.47K	﹤0.01%	3268
2021 Q3	$2K	Buy	+181	New	+$2.76K	﹤0.01%	2720
2020 Q4	–	Sell	-90	Closed	-$2K	–	2696
2020 Q3	$2K	Hold	90	–	–	﹤0.01%	2337
2020 Q2	$2K	Buy	+90	New	+$1.75K	﹤0.01%	2231

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Parallel Advisors's RYTM Position: Q1 2026 in Review

Parallel Advisors held its Rhythm Pharmaceuticals (RYTM) position steady in Q1 2026 at 25 shares worth $2.17K. The position accounts for ﹤0.01% of the portfolio, ranked #3343.

Parallel Advisors first reported a position in RYTM in Q2 2020 and has held it in 14 quarters since. The position peaked at $2.68K in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Parallel Advisors held 25 shares of Rhythm Pharmaceuticals worth $2.17K as of Q1 2026.
Parallel Advisors left its Rhythm Pharmaceuticals share count unchanged in Q1 2026.
Rhythm Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3343 holding.
Parallel Advisors first reported a position in Rhythm Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
Parallel Advisors's Rhythm Pharmaceuticals position peaked at $2.68K in Q4 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.